10
Module 10 of 12
Anticoagulation & Perioperative Management
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)Published: 2026-03-10Updated: 2026-03-10Reviewed: 2026-03-10
Learning Objectives
- Apply current evidence for continuing vs. holding warfarin, DOACs, and antiplatelet agents
- Stratify bleeding risk by procedure type and anatomic site
- Implement hemostasis techniques: chemical, mechanical, and electrosurgical
- Manage postoperative bleeding complications including expanding hematoma
Antithrombotic Medication Management
Antithrombotic medication management is the single most common preoperative clinical question in dermatologic surgery. The key principle: the thromboembolic risk of stopping antithrombotic medications generally far exceeds the manageable bleeding risk of continuing them during cutaneous procedures.
Antiplatelet Agents
Aspirin and P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) are the most commonly encountered antiplatelet agents.
Key Points
- Current evidence strongly supports CONTINUING aspirin for all cutaneous surgical procedures. Stopping aspirin increases thromboembolic risk (stroke, MI) without significantly reducing surgical bleeding
- Dual antiplatelet therapy (DAPT) patients. Typically post-coronary stent. Should continue both agents. Stopping DAPT within the first year post-stent carries a high risk of stent thrombosis, which has a 40% mortality rate
| Agent | Mechanism | Half-life | Recommendation |
|---|---|---|---|
| Aspirin | Irreversible COX-1 inhibition | Platelet lifespan (7–10 days) | CONTINUE for all dermatologic procedures |
| Clopidogrel (Plavix) | Irreversible P2Y12 inhibition | Platelet lifespan | CONTINUE monotherapy; consult cardiology for DAPT concerns |
| Prasugrel (Effient) | Irreversible P2Y12 inhibition | Platelet lifespan | Continue if possible; consult cardiology |
| Ticagrelor (Brilinta) | Reversible P2Y12 inhibition | 7–13 hours | Continue if possible; shorter half-life allows faster reversal if needed |
Warfarin
Warfarin (Coumadin) is a vitamin K antagonist with a well-established evidence base for perioperative management in dermatologic surgery.
Key evidence: CONTINUE warfarin at therapeutic INR (2.0–3.0) for most cutaneous procedures. Multiple studies have demonstrated that the bleeding risk of continuing warfarin is manageable with local hemostasis techniques, while the thromboembolic risk of discontinuation can be life-threatening.
Preoperative protocol:
• Check INR within 72 hours before surgery
• If INR 2.0–3.0: proceed with surgery
• If INR 3.0–3.5: consider proceeding with extra hemostasis vigilance
• If INR >3.5: hold 1–2 doses and recheck; do not operate at supratherapeutic levels
Clinical Pearls
- The evidence is clear: continuing warfarin at therapeutic INR for dermatologic surgery is safer than stopping it. The thromboembolic risk of holding warfarin (1–5%) far exceeds the manageable surgical bleeding risk
- INR should be checked within 72 hours preoperatively. Not earlier, as levels can fluctuate significantly
Important Warnings
- Do not operate on patients with supratherapeutic INR (>3.5). Hold 1–2 doses, recheck, and reschedule if needed. Supratherapeutic INR significantly increases the risk of uncontrollable bleeding
Direct Oral Anticoagulants (DOACs)
DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) have shorter half-lives than warfarin, making perioperative management more straightforward.
Clinical Pearls
- DOACs have shorter half-lives than warfarin, so holding for 24–48 hours provides near-complete elimination without the prolonged anticoagulation gap that warfarin cessation creates
- Many Mohs surgeons now continue DOACs for straightforward cases and hold only for larger flaps or high-bleeding-risk sites (scalp, nose tip)
- Resume DOACs within 24 hours postoperatively. No bridging with heparin is needed
| DOAC | Target | Half-life | Low-Risk Procedure | Higher-Risk Procedure |
|---|---|---|---|---|
| Rivaroxaban (Xarelto) | Factor Xa | 5–9 hours | Continue or hold morning dose | Hold 24–48 hours pre-op |
| Apixaban (Eliquis) | Factor Xa | 8–15 hours | Continue or hold morning dose | Hold 24–48 hours pre-op |
| Dabigatran (Pradaxa) | Thrombin (IIa) | 12–17 hours | Continue or hold morning dose | Hold 24–48 hours (longer if CrCl <50) |
| Edoxaban (Savaysa) | Factor Xa | 10–14 hours | Continue or hold morning dose | Hold 24–48 hours pre-op |
BTK Inhibitors (Emerging Concern)
Bruton’s tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are increasingly used for CLL, lymphoma, and Waldenström’s macroglobulinemia. These agents inhibit collagen-mediated platelet aggregation and significantly increase surgical bleeding risk.
This is an underrecognized issue: many dermatologic surgery patients on BTK inhibitors are not identified preoperatively because these agents are not part of the traditional anticoagulation/antiplatelet screening questions.
Important Warnings
- BTK inhibitors (ibrutinib, acalabrutinib) cause significant platelet dysfunction that increases surgical bleeding risk. Always ask about these agents during preoperative medication review
- Hold ibrutinib 3–7 days preoperatively and resume 1–3 days postoperatively. Consult the prescribing oncologist/hematologist before holding
Bleeding Risk Stratification
Bleeding risk in dermatologic surgery depends on three factors: procedure type, anatomic site, and patient factors.
Procedure & Anatomic Risk
Certain procedures and anatomic sites carry inherently higher bleeding risk due to the vascularity of the tissue and the complexity of the reconstruction.
| Risk Level | Procedures | Anatomic Sites |
|---|---|---|
| Low | Shave biopsy, punch biopsy, small excision with primary closure | Trunk, extremities, non-vascular areas |
| Moderate | Mohs surgery, excision with local flap, FTSG | Forehead, periorbital, cheek |
| High | Large scalp flaps, wedge excision (lip/ear), multiple concurrent procedures | Scalp (highly vascular), nose tip, lip vermilion, temple (superficial temporal artery) |
Patient Risk Factors
Modifiable and non-modifiable patient factors that increase bleeding risk:
Clinical Pearls
- Uncontrolled hypertension is the #1 modifiable risk factor for surgical bleeding. Check blood pressure preoperatively and address if elevated
- Always ask specifically about fish oil, vitamin E, ginkgo, garlic, and turmeric supplements. Patients often do not consider these ‘medications’ and will not volunteer them
| Factor | Risk Impact | Management |
|---|---|---|
| Uncontrolled hypertension | Most important modifiable risk factor | Target BP <150/90 before surgery; recheck in pre-op |
| Anticoagulation/antiplatelet | See medication management section | Continue per evidence-based guidelines with extra hemostasis |
| BTK inhibitors | Significant platelet dysfunction | Hold 3–7 days pre-op (consult oncologist) |
| Supplements (fish oil, vitamin E, ginkgo) | Mild platelet dysfunction | Hold 7–14 days pre-op |
| Hepatic disease | Reduced clotting factor synthesis | Check INR/CBC; plan for extra hemostasis |
| Renal impairment | Uremic platelet dysfunction; affects DOAC clearance | Check GFR; adjust DOAC hold times if CrCl <50 |
| Thrombocytopenia | Reduced platelet count | Check platelet count; generally safe if >50,000 |
Hemostasis Techniques & Hematoma Management
Effective hemostasis is a core surgical skill. Multiple techniques are available, and the surgeon should be facile with all of them to address different bleeding scenarios.
Intraoperative Hemostasis
Hemostasis methods are classified by mechanism:
Clinical Pearls
- Direct pressure for a full 5 minutes (timed) resolves the majority of intraoperative bleeding. The most common error is releasing pressure too early
- For persistent arterial bleeding (pulsatile), identify the vessel and ligate with a figure-of-eight suture. Electrocautery alone often fails for named arteries
| Method | Mechanism | Best For | Cautions |
|---|---|---|---|
| Direct pressure | Mechanical compression of vessels | First-line for all bleeding; diffuse oozing | Must be sustained (3–5 min minimum) |
| Aluminum chloride 20% | Chemical cautery, protein precipitation | Post-biopsy hemostasis, small vessels | Not for large vessel bleeding |
| Ferric subsulfate (Monsel’s) | Chemical cautery, aggressive protein denaturation | Shave biopsy sites | Avoid when Mohs/re-excision planned (pigment artifact) |
| Electrodesiccation | Monoterminal, high-voltage sparking | Small dermal vessels, diffuse oozing | Avoid excessive charring (impairs wound healing) |
| Electrocoagulation (bipolar) | Biterminal current between forceps tips | Named vessels, specific vessel control | Most precise; minimal collateral thermal damage |
| Figure-of-eight suture | Mechanical vessel ligation | Named arteries (temporal, facial branches) | Definitive control for arterial bleeding |
| Absorbable hemostatic agents | Matrix for platelet aggregation | Diffuse oozing in undermined space | Gelfoam, Surgicel, thrombin-soaked Gelfoam |
| Topical tranexamic acid | Antifibrinolytic | Adjunct for diffuse oozing | Emerging evidence in dermatologic surgery |
Postoperative Hematoma Management
Postoperative hematoma is the most common acute complication of dermatologic surgery, occurring in 1–3% of cases. It is most frequent in the first 24–48 hours.
Recognition: rapidly increasing pain, swelling, and tension at the surgical site. The skin may appear blue or ecchymotic. Sutures may appear taut or cutting into edematous skin.
Expanding hematoma management protocol:
1. Open the wound immediately (remove sutures/staples)
2. Evacuate the clot (irrigate and suction)
3. Identify and ligate the bleeding vessel
4. Irrigate thoroughly
5. Reclose the wound in layers
Do NOT apply conservative management (pressure alone) to an expanding hematoma. The trapped blood creates a nidus for infection and the expanding collection will compromise flap vascularity.
Key Points
- Instruct patients to apply firm, direct pressure for 20 minutes if bleeding occurs at home, and to call or present immediately if bleeding does not stop or swelling increases rapidly
- Uncontrolled hypertension in the recovery period is a common precipitant of postoperative hematoma. Ensure BP is controlled before discharge
Important Warnings
- An expanding hematoma is a surgical emergency. The wound must be opened, clot evacuated, and bleeding vessel identified and ligated. Pressure alone is NOT adequate management
- Hematoma in the neck or submandibular region can compress the airway. This is a life-threatening emergency requiring immediate evaluation and potential wound opening
Related Tools & Resources
References
- [1]Trager MH, Burbige RC, Gurnee EA, et al. Management of antithrombotic medications in patients undergoing dermatologic surgery: Part 1. Warfarin and antiplatelet agents. J Am Acad Dermatol. 2025. doi:10.1016/j.jaad.2024.10.072
- [2]Trager MH, Burbige RC, Gurnee EA, et al. Management of antithrombotic medications in patients undergoing dermatologic surgery: Part 2. Direct oral anticoagulants and emerging agents. J Am Acad Dermatol. 2025. doi:10.1016/j.jaad.2024.10.073
- [3]Robinson JK, Hanke CW, Siegel DM, Fratila A. Surgery of the Skin: Procedural Dermatology, 3rd Edition. Elsevier. 2019.
- [4]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer v1.2026. NCCN Guidelines. 2026.
- [5]National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer v1.2026. NCCN Guidelines. 2026.
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program